Cspc Megalith Biopharmaceutical Co.,ltd.
Clinical trials sponsored by Cspc Megalith Biopharmaceutical Co.,ltd., explained in plain language.
-
New combo therapy aims to shrink head and neck tumors
Disease control Recruiting nowThis study tests two experimental drugs, SYS6010 and Enlonstobart, in people with head and neck cancer that has returned or spread. The goal is to see if the combination can shrink tumors and control the disease. About 70 adults aged 18-75 who have not had prior systemic treatmen…
Phase: PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 09, 2026 11:52 UTC
-
New hope for lung cancer patients: experimental drug SYS6010 takes on chemo in major trial
Disease control Recruiting nowThis study tests a new drug called SYS6010 against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has stopped responding to targeted therapy. About 380 adults aged 18-75 will be randomly assigned to rec…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 09, 2026 11:39 UTC
-
New drug SYS6043 aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called SYS6043 in people with advanced or spreading solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors. About 820 adults aged 18 to 75 will take part, receiving different doses to f…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 02, 2026 11:57 UTC